Vaccine R&D success rates and development times

Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R T OliverJ Ong

The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose?

Apr 1, 1995·Journal of Assisted Reproduction and Genetics·M H van Hooff

Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future

Jul 1, 1994·Bio/technology·M M Struck

Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children

Apr 17, 1993·Lancet·E MillerR Tettmar

Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae

Dec 1, 1993·The Journal of Infectious Diseases·C O TacketM M Levine

Reappraisal of existing methods for potency testing of vaccines against tetanus and diphtheria

Aug 1, 1995·Vaccine·R K Gupta, G R Siber

Immunity to diphtheria in northern Norway and northwestern Russia

Sep 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P A JenumH Sjursen

The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand

Sep 12, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Katri AaltonenPauline Norris

❮ Previous

Next ❯

Citations

Development and application of PROVAX adjuvant formulation for subunit cancer vaccines

Jun 6, 2000·Advanced Drug Delivery Reviews·N Hanna, K Hariharan

Leishmania vaccines: old and new

Jun 1, 1997·Parasitology Today·E Handman

Applying the concepts of financial options to stimulate vaccine development

Aug 3, 2006·Nature Reviews. Drug Discovery·David Brogan, Elias Mossialos

Incentives for biodefense countermeasure development

Oct 2, 2007·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Jason MathenyBradley T Smith

Accelerating next-generation vaccine development for global disease prevention

Jun 1, 2013·Science·Wayne C KoffStanley A Plotkin

Emerging respiratory viruses: challenges and vaccine strategies

Oct 17, 2006·Clinical Microbiology Reviews·Laura Gillim-Ross, Kanta Subbarao

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade

Nov 13, 2012·PLoS Neglected Tropical Diseases·Rianna StefanakisMelinda Moree

Risk in vaccine research and development quantified

Mar 26, 2013·PloS One·Esther S PronkerAlbertus D M E Osterhaus

Research and development of new vaccines against infectious diseases

Oct 30, 2004·American Journal of Public Health·Marie Paule KienyMarc Girard

Vaccine R&D: past performance is no guide to the future

Mar 13, 2014·Vaccine·Peter Stephens

Assembling a global vaccine development pipeline for infectious diseases in the developing world

Jul 29, 2006·American Journal of Public Health·Irina Serdobova, Marie-Paule Kieny

Infectious diseases know no borders: a plea for more collaboration between researchers in human and veterinary vaccines.

Apr 15, 2008·The Veterinary Journal·Bernard A M Van der Zeijst

Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications

Jun 7, 2014·Frontiers in Immunology·Sreenivas GannavaramHira L Nakhasi

Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.

Nov 24, 2020·Annals of Internal Medicine·Amanda MacPhersonJonathan Kimmelman

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.

Feb 16, 2021·Lancet·Olivier J WoutersMark Jit

Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D.

May 8, 2021·Frontiers in Public Health·Marga JanseLinda van de Burgwal

The Productivity of Drug Development: A Systematic Review

Nov 13, 2019··Shintaro SengokuTakeshi Akiyama

❮ Previous

Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Vaccine R&D success rates and development times

Abstract

References

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR

A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections

Preclinical safety assessment considerations in vaccine development

Regulatory considerations in vaccine design

Clinical considerations in vaccine trials with special reference to candidate HIV vaccines

Combined seminoma/non-seminoma should be considered as intermediate grade germ cell cancer (GCC)